Susan G Komen  
I've Been Diagnosed With Breast Cancer Someone I Know Was Diagnosed Share Your Story Join Us And Stay Informed Donate To End Breast Cancer
Home > News > Komen News

  


Bookmark and Share

Texas Researchers Studying Breast Cancer Prevention, Minorities, and More Effective Treatments with $8.4 Million from Susan G. Komen for the Cure®

Komen Research Investment in Texas Now Tops $85 Million 


DALLAS – May 23, 2012 – Texas breast cancer researchers will share $8.4 million in new research dollars to develop breakthrough drugs for common breast cancers, more effectively treat advanced forms of the disease, and improve breast cancer outcomes for Latinas, with 2012 research funding from Susan G. Komen for the Cure®.


Komen’s $58 million in new global research grants for the year augment the $685 million that the organization has invested in research since its founding in Dallas in 1982, making it the largest nonprofit funder of breast cancer research outside of the U.S. Government.


With this year’s grants slate, Komen’s research investment in Texas now totals $85 million since 1982.


A complete list and description of Komen’s 2012 grants, including the new peer-reviewed Texas grants, is available here.* The Texas grants include: 


• A $4 million Komen Promise Grant that may lead to the first new drugs in years to treat the most common form of breast cancer – estrogen-driven ER-positive disease diagnosed in about 70 percent of breast cancer cases.  Drs. Bert O’Malley and Kent Osborne of Baylor College of Medicine in Houston will work along two tracks: first, to identify women who won’t benefit from the most commonly used therapies today – tamoxifen or aromatase inhibitors – and second, to develop new treatments that will work. Komen President Elizabeth Thompson called the development of personalized treatments, from the outset of a breast cancer diagnoses, a “critical issue in breast cancer today.”

Baylor College of Medicine is receiving an additional $1.83 million in Komen funding for studies ranging from prevention strategies to clinical trials providing gene testing for medically under-served women. 

• Houston’s UT MD Anderson Cancer Center is receiving another $1.89 million, including $480,000 in new grants aimed studies focusing on metastatic disease, and the Methodist Hospital Research Institute in Houston was awarded $180,000 for studies into using nanotechnology to develop more effective therapies.


• In San Antonio, Dr. Amelie Ramirez of the UT Health Sciences Center is receiving a $250,000 Komen scholar grant to understand why breast cancer outcomes are often worse in Hispanic women and Latinas. Ramirez will examine cultural and economic issues that may be barriers to care for women in the fastest-growing group of women nationwide.


• And in Dallas, Shrikanth Gadad, Ph.D., and mentor, W. Lee Kraus of UT Southwestern Medical School received a $180,000 grant to study the role of a protein in the development and progression of breast cancer that is normally involved in DNA repair.

The research grants augment more than $10 million in 2012 community health grants provided by Komen Affiliates in Houston, Dallas, Ft. Worth, Austin, San Antonio, Waco, Plano, Tyler, Wichita Falls, Texarkana, El Paso, Amarillo and Lubbock.


The community programs served hundreds of thousands of women, providing screenings, education, treatment assistance and financial and social support to Texans facing breast cancer. Seventy-five percent of funds raised by Komen Affiliates remain in their communities to support local breast cancer education, treatment and support programs. The remaining 25 percent funds global research.

“None of this research or progress of the past 30 years would be possible without the generosity of our partners and donors in communities, and we are so grateful for those who understand and support this vital work for all people facing breast cancer,” said Nancy G. Brinker, founder and CEO of Komen for the Cure.

All grants and awards are contingent upon receipt of a fully executed agreement.
*Web table only includes Komen peer-reviewed grants.